Damineh Morsali PH.D., Robert Schwartz Ph.D. Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more ...

Doctors may have discovered another life-saving coronavirus drug ...

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumonia ...

C OVID-19 medicine can help people who are at risk of, diagnosed with, or have symptoms of coronavirus disease 2019 (COVID-19). The medicine helps manage symptoms, stop the virus that causes COVID-19 ...

Roche/Genentech’s Actemra could have a new use soon, after a successful phase 3 trial in the inflamed artery disease, giant cell arteritis. The Switzerland-headquartered company plans to file ...

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab ...

Fresenius, via its operating company Fresenius Kabi, is introducing Tyenne (tocilizumab-aazg), a biosimilar of Actemra (tocilizumab). Tyenne, for use in the treatment of chronic autoimmune ...

Roche is working on a similar anti-inflammatory drug called Actemra that has shown promise in patients who develop respiratory problems. Additionally, Pfizer will test one of its antibiotics in ...

Medically reviewed by Stella Bard, MD Rheumatoid arthritis (RA) is an autoimmune disorder that causes inflammation, pain, and ...

On April 15, 2024, Fresenius Kabi announced the U.S. launch of its ACTEMRA biosimilar, TYENNE (tocilizumab-aazg) as an intravenous formulation. As we previously reported, Fresenius Kabi received ...

Those sales were, however, pulled down significantly by slower sales of diagnostics tests for COVID-19 and of its medicines Actemra and Ronapreve, which it gained a license to manufacture and sell ...